Similarly, the progression-free interval (PFI) (p = 0.0041, HR (95% CI) 0.60 (0.40–0.91)), disease-free interval (DFI) (p = 0.0033, HR (95% CI) 0.20(0.10–0.41)), and disease-specific survival (DSS) (p = 0.023, HR (95% CI) 0.49 (0.30–0.80)) consistently showed a survival trend (Fig. 3b), indicating that higher expression of GGT5 was closely related to adverse clinical outcomes in GC patients. The gene discussed is GGT5; the disease is gastric cancer.